Marilyn Agee, MD
Family Medicine · Toledo, OHNPI 1306841598
Payments from drug & device makers
Across 165 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$407
- Pfizer$378
- Novo Nordisk$278
- AstraZeneca$223
- Lilly USA, LLC$161
- Novartis$115
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $407 |
| Pfizer | 27 | $378 |
| Novo Nordisk | 11 | $278 |
| AstraZeneca | 8 | $223 |
| Lilly USA, LLC | 10 | $161 |
| Novartis | 7 | $115 |
| Bayer | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 5 | $84 |
| Boehringer Ingelheim | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 4 | $60 |
| Dexcom, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Exact Sciences | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $41 |
| Amgen | 3 | $39 |
| Halozyme Inc | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Phadia US Inc. | 2 | $34 |
| Eisai Inc. | 2 | $28 |
| Corcept Therapeutics | 1 | $24 |
| Abbott | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Smith+Nephew | 1 | $21 |
| Corium, LLC | 1 | $17 |
| Gilead | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$124
How this compares
$2,812 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $82,464 |
| MounjaroTirzepatide | 52 | $63,551 |
| EliquisApixaban | 59 | $60,294 |
| JanuviaSitagliptin Phosphate | 53 | $59,190 |
| OzempicSemaglutide | 31 | $42,567 |
| TrulicityDulaglutide | 20 | $38,776 |
| FarxigaDapagliflozin Propanediol | 13 | $20,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,394 |
| MyrbetriqMirabegron | 17 | $11,117 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $7,392 |
| MovantikNaloxegol Oxalate | 12 | $7,251 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $6,596 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,907 |
| Atorvastatin Calcium | 434 | $5,549 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $161 | $102,32772 claims |
| Boehringer IngelheimJardiance | $82 | $82,46471 claims |
| PfizerEliquis | $378 | $60,29459 claims |
| MerckJanuvia | $16 | $59,19053 claims |
| Novo NordiskOzempic | $278 | $42,56731 claims |
| AstraZenecaFarxiga | $223 | $20,73513 claims |
| GSKTrelegy Ellipta | $64 | $17,39421 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $11,11717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Toledo
- Henry NaddafToledo$252K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.